TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16498052
Drug: High-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat diet (HF) - 0.5 g fat/kg BW per day for 1 day followed by 3.5 g fat/kg BW per day for 1.5 days
Study: 15007562
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow injection (15 ml) at the fracture site and casting
Study: 9836064
Drug: Panicogenic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panicogenic doses of caffeine administered to PD patients
Study: 9836064
Drug: Panicogenic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panicogenic doses of caffeine administered to healthy volunteers
Study: 7659767
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2-mg pieces, up to 30 per day) with reinforcement of lottery tickets for CO < 10 ppm
Study: 6807878
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg erythromycin ethyl succinate intramuscularly
Study: 6807878
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg erythromycin stearate orally
Study: 30885685
Drug: AG10 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG10 400 mg
Study: 30885685
Drug: AG10 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG10 800 mg
Study: 29935541
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual + training of the GP (intervention group)
Study: 26024926
Drug: Polyethylene glycol‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol‐electrolyte oral solution (PEG‐EOS)
Study: 2193839
Drug: Frusemide/amiloride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide/amiloride (20 mg frusemide/2.5 mg amiloride daily)
Study: 2193839
Drug: Bumetanide/potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide/potassium chloride (0.5 mg bumetanide/573 mg potassium chloride daily)
Study: 30580092
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (clopidogrel and low-dose aspirin)
Study: 19994684
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine (Metoprolol, Propafenone, Aspirin)
Study: 11727735
Drug: Trinam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trinam (1 x 10^11 viral particles, single administration)
Study: 7506187
Drug: Nimesulide 800mg
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 800mg daily
Study: 7506187
Drug: Nimesulide 400mg
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 400mg daily
Study: 7506187
Drug: Nimesulide 600mg
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 600mg daily
Study: 7506187
Drug: Nimesulide 200mg
Normalized name: nimesulide 200 MG
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 200mg daily
Study: 7506187
Drug: Nimesulide 300mg
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 300mg daily
Study: 2882234
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous adrenaline
Study: 28889834
Drug: Interviewer-administered dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interviewer-administered dietary recalls
Study: 25310993
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Lupron Depot (22.5 mg leuprolide acetate)
Study: 25310993
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Lupron Depot (11.25 mg leuprolide acetate)
Study: 23452187
Drug: BCG induction
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG induction therapy or BCG induction plus maintenance
Study: 17611132
Drug: Zafirlukast (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (40 mg orally the evening before and 40 mg the morning of assessment)
Study: 12883229
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 1800 mg/d
Study: 12883229
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) 1000 mg/d
Study: 10969365
Drug: Pre MB
Normalized name: Ionosol-MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre MB (morphine and bupivacaine)
Study: 10969365
Drug: Pre M
Normalized name: Pre Milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre M (morphine)
Study: 10969365
Drug: Post MB
Normalized name: Ionosol-MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post MB (morphine and bupivacaine)
Study: 1451724
Drug: O-(beta-hydroxyethyl)-rutosides (HR)
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O-(beta-hydroxyethyl)-rutosides (HR) 2 x 1.5 g IV before surgery
Study: 6396153
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral co-trimoxazole
Study: 6396153
Drug: Five-day oral
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day oral co-trimoxazole
Study: 30807389
Drug: Microneedling followed
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling followed by PMMA-collagen gel filler
Study: 8435171
Drug: Preoperative steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative steroid treatment (methylprednisolone)
Study: 8435171
Drug: Postoperative steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative steroid treatment (methylprednisolone)
Study: 8435171
Drug: SK&F 86002
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK&F 86002 (nonsteroidal dual cyclooxygenase/lipooxygenase inhibitor)
Study: 8435171
Drug: Delayed steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed steroid administration
Study: 8435171
Drug: Preoperative steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative steroid therapy (in double-blinded placebo-controlled study)
Study: 3304117
Drug: Verapamil (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (360 mg/24 h)
Study: 3304117
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg/24 h)
Study: 24013685
Drug: Baseline UPCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline UPCR < 1.0 g/gCr
Study: 24013685
Drug: Residual UPCR
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual UPCR ≥ 1.0 g/gCr and ΔUPCR <30%
Study: 20805623
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin, 50 U/kg
Study: 20805623
Drug: Standard-dose unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose unfractionated heparin, 85 U/kg (60 U/kg with GpIIb‐IIIa inhibitors)
Study: 16760927
Drug: Risperidone augmentation
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone augmentation (0.25-2.0 mg/day)
Study: 16760927
Drug: Risperidone augmentation
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone augmentation (0.25-2.0 mg/day) in fully nonresponsive patients
Study: 16760927
Drug: Placebo augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo augmentation in fully nonresponsive patients
Study: 9663833
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ABT-229
Study: 9663833
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg ABT-229
Study: 3527181
Drug: suprofen syrup
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: suprofen syrup 10 mg/ml
Study: 21490622
Drug: Successful anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful anti-hypertensive treatment
Study: 20954414
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy and kinesy-therapy
Study: 20954414
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current and kinesy-therapy
Study: 18296423
Drug: Ixabepilone 6
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 6 mg/m(2)/day x 5 days every 21 days (arm A)
Study: 18296423
Drug: Ixabepilone 20
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 20 mg/m(2) on days 1, 8, and 15 of a 28-day cycle (arm B)
Study: 18296423
Drug: Weekly ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly ixabepilone 20 mg/m(2)
Study: 14765564
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment system
Study: 8886909
Drug: Methylprednisolone (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (2000 mg 2‐3 hours before cisplatin)
Study: 1303780
Drug: cyclosporin A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporin A, daily dose of 100 mg for 2 years
Study: 24694205
Drug: Low vitamin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vitamin B12 group (B12 < 221 pmol/l)
Study: 22566538
Drug: Iron plus
Normalized name: Nu-Iron Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron plus folic acid (12.5 mg of iron and 50 μg of folic acid)
Study: 18565127
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 or 2550 mg/day for 8 months
Study: 10609921
Drug: DCLHb as
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb as an adjunct to standard therapy
Study: 1657502
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation at 50 litres/min
Study: 1657502
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation at 100 litres/min
Study: 1657502
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid inhalation at 50 litres/min
Study: 6355047
Drug: Acyclovir low
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir low dose (5 mg/kg every 8 h)
Study: 6355047
Drug: Acyclovir high
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir high dose (500 mg/m2 every 8 h)
Study: 31665746
Drug: Micronutrient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient treatment (up to 12 capsules/day)
Study: 16220331
Drug: Ketamine (60-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (60-min infusion)
Study: 8528821
Drug: Outpatient, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient, once a week group treatment for sexually abused girls
Study: 2222351
Drug: Nasal histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal histamine (maximum nasal dose of 250 micrograms)
Study: 31910803
Drug: Home-based computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based computerized executive function training programme (12 weeks, 5 days a week, 30 min a day training, total dose = 30 h)
Study: 23461009
Drug: Reamberin 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin 1.5% infusion
Study: 23461009
Drug: Official therapy
Normalized name: Fumaria officials whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Official therapy
Study: 15687942
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + clavulanic acid 1g/125 mg administered from ovum pick-up day for 6 days
Study: 9450157
Drug: pivagabine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivagabine (900 mg/d)
Study: 7949210
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg 4-hydroxyandrostenedione i.m. fortnightly
Study: 7949210
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg 4-hydroxyandrostenedione i.m. fortnightly
Study: 3048754
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg.kg‐1 IV
Study: 3048754
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg.kg‐1 IV
Study: 28453754
Drug: Once-daily mesalazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily mesalazine
Study: 28453754
Drug: Twice-daily mesalazine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily mesalazine
Study: 18817348
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (oral hydrochloric acid sertraline, local inunction of traditional Chinese medicine, guidance in sexual psychology and knowledge)
Study: 18817348
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral hydrochloric acid sertraline only)
Study: 11944739
Drug: Selegiline, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline, 5 mg, twice a day for 3 months
Study: 20973966
Drug: Fenofibrate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (300 mg/day for 25 weeks)
Study: 12010234
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for penile fracture
Study: 10660868
Drug: Ginseng (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (n = 7), receiving 350 mg of ginseng daily for 6 weeks
Study: 10660868
Drug: Placebo (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (n = 8), receiving a placebo daily for 6 weeks
Study: 7848024
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg twice daily vs Losartan 100 mg once daily
Study: 7848024
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily vs Losartan 50 mg twice daily
Study: 7848024
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of hydrochlorothiazide 12.5 mg/d
Study: 367153
Drug: Low-calcium meal
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium meal (100 mg)
Study: 367153
Drug: High-calcium meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium meal (400 mg)
Study: 31795748
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive treatment (n=38)
Study: 31795748
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive treatment + intermittent pneumatic compression (n=38)
Study: 31134436
Drug: No laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: No laser treatment
Study: 23370739
Drug: Pramipexole added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole added to current medications
Study: 23370739
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from ergot dopamine agonist to pramipexole
Study: 21081553
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PTFE membrane and synthetic PEG
Study: 785019
Drug: Antacid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid therapy
Study: 785019
Drug: No antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antacid therapy
Study: 31246632
Drug: Enteral plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral plus Total Parenteral Nutrition (EN+TPN)
Study: 17874717
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTA) and physical therapy
Study: 11721321
Drug: OCA 1
Normalized name: STARCH, TAPIOCA 15.81 g in 100 mL TOPICAL CREAM [GZE Man Ball Deodorant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA 1 (omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, twice daily for one week)
Study: 11721321
Drug: OCA 2
Normalized name: Avoca 25 % / 75 % Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA 2 (omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, twice daily for two weeks)
Study: 11721321
Drug: OCM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCM (omeprazole 20 mg, clarithromycin 500 mg, metronidazole 500 mg, twice daily for one week)
Study: 9248896
Drug: Liquid nitrogen
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid nitrogen therapy
Study: 9248896
Drug: Other known
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other known treatment modalities
Study: 2889555
Drug: Vecuronium (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (60 micrograms/kg bolus + 1 microgram/min/kg infusion) with halothane anesthesia
Study: 2889555
Drug: Vecuronium (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (60 micrograms/kg bolus + 1 microgram/min/kg infusion) with fentanyl anesthesia
Study: 30152527
Drug: SENS-111 (100-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: SENS-111 (100-500 mg single doses; 50-150 mg/day for 4 days; 200-250 mg/day for 7 days)
Study: 30152527
Drug: SENS-111 (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SENS-111 (100-200 mg/day)
Study: 23982695
Drug: Lyophilized black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized black raspberries (BRBs) 45 g/d for 4 days followed by HFHC breakfast with BRBs
Study: 20966375
Drug: Standard Shape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Shape Up RI program plus video lessons, daily self-monitoring of weight, eating, and exercise, and computer-generated feedback (Study 2)
Study: 705282
Drug: Traditional physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional physiotherapy treatment (1 hour/day)
Study: 25959558
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose followed by 10 mg daily maintenance dose (n=19)
Study: 25959558
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose followed by 90 mg twice daily maintenance dose (n=20)
Study: 23746674
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation (CRT) to a dose of 66 Gy in 33 fractions over 6.5 weeks with concurrent cisplatin (100 mg/m(2) on days 1, 22 and 43)
Study: 23746674
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy with concomitant boost (CBRT) to a dose of 67.5 Gy in 40 fractions over 5 weeks
Study: 16734237
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg IM
Study: 16734237
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg IV
Study: 8428787
Drug: Usual alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual alcohol drinking (self-reported 56.1 +/- 3.6 ml/day)
Study: 28200002
Drug: AbobotulinumtoxinA solution
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA solution for injection (ASI) 20 U
Study: 28200002
Drug: AbobotulinumtoxinA solution
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA solution for injection (ASI) 75 U
Study: 25455987
Drug: MVA-H5-sfMR vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-H5-sfMR vaccine at 10^8 pfu
Study: 25455987
Drug: MVA-H5-sfMR vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-H5-sfMR vaccine at 10^7 pfu
Study: 22928785
Drug: Danusertib 330
Normalized name: Danusertib
DrugBank: Danusertib (DB11778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danusertib 330 mg/m2 over 6 h i.v. on days 1, 8 and 15 (arm A)
Study: 22928785
Drug: Danusertib 500
Normalized name: Danusertib
DrugBank: Danusertib (DB11778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danusertib 500 mg/m2 over 24 h i.v. on days 1 and 15 (arm B)
Study: 19887460
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (10 mg/kg/day for the first 14 days)
Study: 18704249
Drug: Tolterodine tartrate
Normalized name: Tolterodine Tartrate
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolterodine tartrate extended-release capsules 4 mg
Study: 18704249
Drug: Tolterodine tartrate
Normalized name: Tolterodine Tartrate
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolterodine tartrate extended-release capsules 4 mg with behavioral therapy
Study: 15752098
Drug: n-butanol solutions
Normalized name: BUTANOLS
DrugBank: Butyl alcohol (DB02145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-butanol solutions (0 to 90,000 ppm)
Study: 8779366
Drug: 2000 ml
Normalized name: TPN Bag 2000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 ml of Ringer lactate solution (crystalloid group)
Study: 8779366
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of 6% hydroxyethyl starch + 1000 ml of Ringer lactate solution (colloid group)